Atlas Trials

An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy

Clinical trial NCT01664533 · COMPLETED

Trial details

NCT number
NCT01664533
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Study type
OBSERVATIONAL
Non-Squamous Non-Small Cell Lung Cancer
Start date
2011-09-01
Primary completion
2013-08-01
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.